Skip to main content
Fig. 5 | Cell Communication and Signaling

Fig. 5

From: Proximity proteome mapping reveals PD-L1-dependent pathways disrupted by anti-PD-L1 antibody specifically in EGFR-mutant lung cancer cells

Fig. 5

Anti-PD-L1 antibody treatment affects extracellular vesicles. A Venn diagram of EV proteins with the highest intensities (top quartile) in each of the cell lines. B Biological processes representing proteins that are most enriched in the EVs of H1650 cells. Fold enrichment and FDR for the pathways are shown. C Heatmap of Durvalumab-induced fold change of extracellular vesicle marker proteins expression in (C) EV fraction and D whole cell lysate in BEAS-2B and H1650. E Durvalumab-induced fold change of extracellular vesicle-enriched proteins (top quartile for each cell line) in BEAS-2B, A549 and H1650. For C–E cells were treated with Durvalumab. Average + / − Durvalumab value for N = 2 is shown. F Schematic of H1650 PD-L1-APEX2 proximity map shared with BEAS-2B and unique to H1650

Back to article page